Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Vandana Singh

Harpoon Therapeutics Discontinues Its Once Lead Prostate Cancer Candidate

Harpoon Therapeutics Inc (NASDAQ:HARP), in its Q4 FY21 earnings results, has given up on its onetime lead prospect HPN424. 

  • "We are focusing our resources on portfolio programs that show promising activity, including HPN328 and HPN217, while we advance new candidates into the clinic from our technology platforms," said Julie Eastland, President & CEO.
  •  "Additionally, we have conducted a careful and thorough analysis of our HPN424 data...we have decided to discontinue the HPN424 dose-escalation study," Eastland added.
  • Harpoon used HPN424 as the centerpiece of an IPO filing.
  • In June last year, the Company presented interim data from the dose-escalation portion of a Phase 1/2a trial of HPN424 in metastatic castration-resistant prostate cancer (mCRPC).
  • Dose Limiting Toxicities were observed at doses ranging from 96 to 300ng/kg.
  • Harpoon went into 2022, aiming to complete dose-escalation 2H of 2022.
  • Harpoon expects to determine the Phase 2 doses of HPN328, a drug for tumors associated with DLL3 expression, and BCMA prospect HPN217 by 2022.
  • Harpoon ended 2021 with $136.6 million in cash, cash equivalents, and marketable securities.
  • Price Action: HARP shares are down 13.6% at $4.68 during the market session on the last check Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.